Match Document Document Title
US20160193152 METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS  
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the...
US20160145198 COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS  
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said...
US20150030675 Controlled Release Dosage Forms  
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°...
US20100190793 COMPOSITIONS FOR AFFECTING WEIGHT LOSS  
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased...
US20090012180 Titration of Tapentadol  
The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of...
US20070275970 COMPOSITIONS FOR AFFECTING WEIGHT LOSS  
Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased...
US20070202054 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid  
An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can...
US20070105843 COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST  
The present invention relates to the use of compounds and compositions of compounds having serotonin reuptake inhibiting activity and 5-HT2C antagonistic, partial agonistic or inverse agonistic...
US20070053996 LIGHT-ACTIVATED CATION CHANNEL AND USES THEREOF  
The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for...
US20060039987 Method and apparatus for producing dry particles  
Method and apparatus for producing dry particles. Two liquid components are combined in a static mixer, atomized into droplets, and the droplets dried to form dry particles. Use of the static...
US20050276830 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders  
In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is...
US20050192210 Compositions and methods for treating diseases  
This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of...
US20050176680 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression  
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The...
US20050158384 Sustained release delivery of amphetamine salts  
A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients...
US20050119160 Methods and reagents for the treatment of immunoinflammatory disorders  
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted...
US20050058706 Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol  
A pharmaceutical formulation for delayed release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing...
US20160338977 METHODS AND KITS FOR TREATING DEPRESSION  
The present invention is directed to, inter alia, methods and kits for the treatment of depression (preferably, treatment resistant depression), or for the treatment of depression in a suicidal...
US20080132578 Dosage forms of O-desmethylvenlafaxine  
Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited...
US20080044482 ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT  
Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for...
US20070281012 MODIFIED RELEASE FORMULATIONS OF A BUPROPION SALT  
The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of...
US20070203247 EPINEPHRINE DOSING REGIMENS  
The present invention relates to methods for administering a first dose of epinephrine solution and an optional second dose of epinephrine solution. Also provided herein are kits useful in these...
US20070129283 Compositions and methods for reducing food cravings  
Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an α-MSH...
US20070099909 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR  
The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
US20060069086 Methods for regulating neurotransmitter systems by inducing counteradaptations  
The present invention relates to methods for regulating neurotransmitter systems by inducing a counteradaptation response. According to one embodiment of the invention, a method for regulating a...
US20060058293 Combination of bupropion and a second compound for affecting weight loss  
Disclosed are compositions for affecting weight loss comprising bupropion and a second compound, where the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a...
US20050245617 Methods and compositions for the treatment of CNS-related conditions  
The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease.
US20050181049 Composition and method for enhancing bioavailability  
The present invention relates to compositions and methods for enhancing the bioavailability of beneficial agents with low water solubility.
US20120172392 AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES  
Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing...
US20100260810 ANTIDEPRESSANT DOSAGE FORM  
The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
US20090232886 ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING  
Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical...
US20080014274 Enhanced stability phenylephrine liquid compositions  
An oral, liquid pharmaceutical composition is provided. The composition comprises phenylephrine and substantially aldehyde-free polyethylene glycol. The composition has phenylephrine stability...
US20070292510 ENTERIC COATED PARTICLES CONTAINING AN ACTIVE INGREDIENT  
Enterically coated particles and chewable tablets made therefrom are disclosed. The enterically coated particles are comprised of a core containing an active ingredient, a first coating layer...
US20070270372 Organ arrest, protection and preservation  
The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an...
US20070112017 GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS  
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes...
US20070078157 Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases  
Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing...
US20070004718 Ion channel modulating compounds and uses thereof  
Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and...
US20060127473 Compositions and methods for stabilizing active pharmaceutical ingredients  
The present invention relates to stable pharmaceutical compositions having an unstable active pharmaceutical ingredient.
US20060025438 Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases  
Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing...
US20050271661 Methods and reagents for the treatment of immunoinflammatory disorders  
The invention involves the treatment, prevention, and reduction of immunoinflammatory disorders involving the combination of an agent that increases the signal activity of a glucocorticoid...
US20050250738 Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin  
The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are...
US20050191350 Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof  
Provided are formulations of a stable commercial paroxetine tablet comprising paroxetine hydrochloride anhydrous, povidone, copovidone or HPMC as a binder, and an HCl free/non-hygroscopic filler,...
US20050165098 Local anesthetic methods and kits  
Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing...
US20100125070 Bupropion Metabolites and Methods of Their Synthesis and Use  
Methods and compositions are disclosed which utilize metabolites of bupropion for treating disorders ameliorated by inhibition of neuronal monoamine reuptake. Such disorders include, but are not...
US20090099202 External Preparation for Athlete's Foot Treatment  
External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at...
US20080286356 Pharmaceutical compositions containing terbinafin and use thereof  
Pharmaceutical compositions for oral administration comprising terbinafine and a method for administering high dosages while minimizing effects associated with e.g. a high dosage load, e.g. coated...
US20080187584 Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof  
Provided are formulations of a stable paroxetine hydrochloride tablet comprising paroxetine hydrochloride, povidone or copovidone as a binder, and an HCl free/non-hygroscopic filler, prepared by...
US20080103179 Combination Therapy  
The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves...
US20070293548 Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases  
Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of...
US20070275060 Extended release solid pharmaceutical composition containing carbidopa and levodopa  
The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally...
US20070254027 Compositions and methods useful for treatment of respiratory illness  
Disclosed are compositions including phenylephrine, its salts, and mixtures thereof, in combination with acetaminophen; and optionally in combination with additional pharmaceutical actives. The...